Bio Key International INC (BKYI) — SEC Filings

Overview

Bio Key International INC (BKYI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 31, 2026: Bio-Key International, Inc. filed an 8-K on March 31, 2026, reporting its results of operations and financial condition for the period ending March 31, 2026. The filing includes financial statements and exhibits, with the primary document being the 8-K itself in iXBRL format.

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 1 bullish, 8 bearish, 28 neutral, 3 mixed. The dominant filing sentiment for Bio Key International INC is neutral.

Filing Type Overview

Bio Key International INC (BKYI) has filed 22 8-K, 4 S-1, 5 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 1 10-K/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• 8-K Filing — 8-K · Apr 20, 2026
• Bio-Key International Files 8-K for Q1 2026 Results — 8-K · Mar 31, 2026 Risk: low
  Bio-Key International, Inc. filed an 8-K on March 31, 2026, reporting its results of operations and financial condition for the period ending March 31, 2026. Th
• BIO-key Files S-1 for 6.18M Share Resale, Eyes $6.3M from Warrant Exercise — S-1 · Nov 21, 2025 Risk: high
  BIO-key International, Inc. (BKYI) filed an S-1 to register the resale of up to 6,183,336 shares of common stock by a selling stockholder, issuable upon the exe
• BIO-key's Q3 Loss Widens Amid Revenue Dip, Cash Boosted by Warrants — 10-Q · Nov 14, 2025 Risk: high
  BIO-KEY INTERNATIONAL INC (BKYI) reported a net loss of $964,849 for the three months ended September 30, 2025, an increase from a net loss of $738,959 in the p
• BIO-key International Faces Delisting Concerns — 8-K · Nov 7, 2025 Risk: high
  BIO-key International, Inc. filed an 8-K on November 7, 2025, reporting a notice of delisting or failure to meet continued listing standards. The company, incor
• BIO-key International Files 8-K with Material Agreements — 8-K · Oct 30, 2025 Risk: medium
  On October 27, 2025, BIO-key International, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securit
• BIO-key International Enters Material Definitive Agreement — 8-K · Oct 3, 2025 Risk: medium
  On September 30, 2025, BIO-key International, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporat
• BIO-key International Announces Board and Officer Changes — 8-K · Aug 20, 2025 Risk: medium
  On August 8, 2025, BIO-key International, Inc. filed an 8-K report detailing changes in its board of directors and executive officers, including the appointment
• BIO-key Narrows Q2 Loss on Hardware Surge, Cash Up from Warrants — 10-Q · Aug 13, 2025 Risk: high
  BIO-KEY INTERNATIONAL INC (BKYI) reported a net loss of $1,167,396 for the three months ended June 30, 2025, a significant improvement from the $1,666,950 net l
• BIO-KEY's 2024 Equity Compensation: A Zero-Sum Game? — DEF 14A · Jun 27, 2025 Risk: medium
  BIO-KEY INTERNATIONAL INC's DEF 14A filing, dated June 27, 2025, primarily details executive compensation for the fiscal years ending December 31, 2022, 2023, a
• Bio-Key International Reports Q1 2025 Revenue Growth — 10-Q · May 15, 2025 Risk: medium
  Bio-Key International Inc. reported its first quarter 2025 results, with total revenues of $5.814 million for the period ending March 31, 2025. This compares to
• BIO-key International Files S-1 Registration — S-1 · Apr 25, 2025 Risk: medium
  BIO-key International, Inc. filed an S-1 registration statement on April 25, 2025, to register securities under the Securities Act of 1933. The company, formerl
• Bio-key International Faces Delisting Concerns — 8-K · Apr 24, 2025 Risk: high
  Bio-key International, Inc. filed an 8-K on April 24, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company's princip
• Bio-Key International Inc. Files 2024 10-K — 10-K · Apr 23, 2025 Risk: medium
  Bio-Key International Inc. reported its 2024 fiscal year results, emphasizing a defense-in-depth security approach to protect data and infrastructure. The compa
• BIO-key International Files 8-K Report — 8-K · Mar 27, 2025 Risk: low
  On March 27, 2025, BIO-key International, Inc. filed an 8-K report detailing its financial results and exhibits. The company, incorporated in Delaware, is headq
• BIO-key International Reports Material Agreement and Equity Sales — 8-K · Jan 16, 2025 Risk: medium
  On January 15, 2025, BIO-key International, Inc. entered into a material definitive agreement. The company also reported unregistered sales of equity securities
• BIO-key International Files 8-K: Material Agreement, Equity Sales — 8-K · Dec 3, 2024 Risk: medium
  On November 27, 2024, BIO-key International, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The
• BIO-KEY INTERNATIONAL INC Files 8-K on Financials — 8-K · Nov 15, 2024 Risk: low
  Bio-key International, Inc. filed an 8-K on November 15, 2024, reporting on its results of operations and financial condition as of November 14, 2024. The filin
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Bio-Key International Reports Q3 2024 Results — 10-Q · Nov 14, 2024 Risk: medium
  Bio-Key International Inc. reported its Q3 2024 results, ending September 30, 2024. The company's total assets were $3,109,288, with total liabilities amounting
• BIO-key International Files S-1 with SEC — S-1 · Oct 11, 2024 Risk: medium
  BIO-key International, Inc. filed an S-1 registration statement with the SEC on October 11, 2024. The company, previously known as SAC Technologies Inc., is inc
• BIO-key International Files 8-K with Material Agreement — 8-K · Sep 16, 2024 Risk: medium
  On September 12, 2024, BIO-key International, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. Th
• BIO-key International Shareholder Meeting Vote Results Pending — 8-K · Aug 28, 2024 Risk: low
  On August 22, 2024, BIO-key International, Inc. filed an 8-K report detailing a shareholder meeting where proposals were voted upon. The specific outcomes of th
• BIO-key International Files 8-K on Financials — 8-K · Aug 15, 2024 Risk: medium
  On August 14, 2024, BIO-key International, Inc. filed an 8-K report detailing its financial results and condition. The company, incorporated in Delaware, is inv
• Bio-Key International Reports Q2 2024 Results — 10-Q · Aug 14, 2024 Risk: medium
  Bio-Key International Inc. reported its Q2 2024 financial results, ending June 30, 2024. The company had total assets of $1,815,618 and total liabilities of $1,
• Bio-Key International Files Annual Proxy Statement — DEF 14A · Jul 10, 2024 Risk: medium
  Bio-Key International Inc. filed its DEF 14A on July 10, 2024, for the fiscal year ending December 31, 2023. The filing pertains to the company's annual meeting
• BIO-key International Secures $1.5M Loan — 8-K · Jun 28, 2024 Risk: medium
  On June 24, 2024, BIO-key International, Inc. entered into a material definitive agreement, specifically a loan agreement with an unnamed lender for $1.5 millio
• Bio-Key International Files 2023 Annual Report Amendment — 10-K/A · Jun 20, 2024 Risk: low
  Bio-Key International, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The filing, dated June 20, 2024, provi
• BIO-key International Files 8-K Report — 8-K · Jun 17, 2024 Risk: low
  On June 17, 2024, BIO-key International, Inc. filed an 8-K report detailing its financial results and exhibits. The company, incorporated in Delaware, is headqu
• BIO-key International Faces Nasdaq Delisting Warning — 8-K · Jun 14, 2024 Risk: high
  On June 10, 2024, BIO-key International, Inc. received a notification from The Nasdaq Stock Market LLC regarding its failure to meet the minimum bid price requi
• Bio-Key International Inc. 2023 10-K Filed — 10-K · Jun 5, 2024 Risk: medium
  Bio-Key International Inc. filed its 2023 10-K on June 5, 2024, reporting total assets of $7,020,258 and total liabilities of $1,789,720 as of December 31, 2023
• BIO-key International Faces Delisting, Plans Reverse Split — 8-K · May 24, 2024 Risk: high
  BIO-key International, Inc. filed an 8-K on May 24, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company is address
• BIO-key International Changes Auditors — 8-K · Apr 30, 2024 Risk: medium
  BIO-key International, Inc. announced on April 23, 2024, a change in its certifying accountant. The company has dismissed Marcum LLP as its independent register
• BIO-key International Faces Delisting Warning & Restates Financials — 8-K · Apr 22, 2024 Risk: high
  BIO-key International, Inc. filed an 8-K on April 22, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of April 16, 2024.
• BIO-key International Files 8-K on Financials — 8-K · Apr 2, 2024 Risk: low
  BIO-key International, Inc. filed an 8-K on April 2, 2024, reporting on its results of operations and financial condition as of April 1, 2024. The filing includ
• SC 13G Filing — SC 13G · Feb 14, 2024
• Lind Global Fund II Amends BIO-key Stake Disclosure — SC 13G/A · Feb 13, 2024 Risk: low
  Lind Global Fund II LP, a New York-based investment firm, filed an Amendment No. 3 to its SC 13G filing on February 13, 2024, indicating its ownership of BIO-ke
• BIO KEY INTERNATIONAL INC. Files S-1 Registration Statement — S-1 · Jan 30, 2024 Risk: low
  BIO KEY INTERNATIONAL INC (BKYI) filed a IPO Registration (S-1) with the SEC on January 30, 2024. BIO KEY INTERNATIONAL INC. filed an S-1 registration statement
• AJB Capital Investments Updates BIO-KEY Stake to 26,137 Shares — SC 13G/A · Jan 25, 2024
  AJB Capital Investments LLC, a Florida-based investment firm, filed an amended Schedule 13G on January 25, 2024, disclosing its beneficial ownership in BIO-KEY
• BIO-key Files 8-K for 'Other Event' on Jan 8, 2024 — 8-K · Jan 11, 2024
  BIO-key International, Inc. filed an 8-K on January 11, 2024, reporting an 'Other Event' that occurred on January 8, 2024. This filing is a routine disclosure i

Risk Profile

Risk Assessment: Of BKYI's 35 recent filings, 8 were flagged as high-risk, 18 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bio Key International INC's most recent 10-Q filing (Nov 14, 2025):

• Revenue: $1,549,706
• Net Income: -$964,849
• EPS: N/A
• Debt-to-Equity: 0.67
• Cash Position: $2,039,853
• Operating Margin: N/A
• Total Assets: $10,113,313
• Total Debt: $4,068,235

Key Executives

• Michael DePasquale
• Vincent A. Vietti
• 7323591100
• JEFF EASTON

Industry Context

BIO-key operates in the Identity Access Management (IAM) sector, a growing market driven by increasing cybersecurity threats and the need for secure digital access. The company competes with established players and emerging solutions, focusing on biometric authentication and multi-factor authentication. Key growth areas include government, higher education, and highly-regulated industries, where robust security is paramount.

Top Tags

financials (6) · material-agreement (5) · financial-reporting (4) · delisting (4) · equity-sale (4) · 8-k (4) · results-of-operations (3) · Biometrics (3) · earnings (3) · annual-report (3)

Key Numbers

• Shares of Common Stock Offered: 6,183,336 — Represents approximately 36% of outstanding common stock post-warrant exercise, indicating significant potential dilution.
• Expected Proceeds from Warrant Exercise: $6.31M — Funds for working capital and debt repayment, crucial for company operations and strategic initiatives.
• Closing Stock Price: $1.03 — As of November 18, 2025, providing a baseline for potential market impact.
• Common Stock Outstanding: 10,836,618 — As of November 13, 2025, before the potential exercise of warrants.
• Dilution Percentage: 36% — Approximate percentage of outstanding common stock represented by the shares offered, assuming full warrant exercise.
• Strong Authentication Factors: 17 — Number of authentication factors leveraged by BIO-key's biometric core platform.
• Bank Customers Identified: 21.7M — Number of customers a large bank identifies using BIO-key fingerprint biometrics daily.
• Channel Alliance Program Participants: 85 — Number of participants in BIO-key's growing channel alliance program.
• Acquisition Year: 2022 — Year BIO-key acquired Swivel Secure, expanding its product offerings and customer base.
• Weighted Average Contract Duration: 1 — In years, for noncancelable subscription contracts, indicating recurring revenue stability.
• Net Loss (Q3 2025): $964,849 — Increased from $738,959 in Q3 2024, indicating worsening quarterly profitability.
• Net Loss (YTD 2025): $2,868,790 — Slightly improved from $2,916,195 in YTD 2024, but still a significant loss.
• Total Revenues (Q3 2025): $1,549,706 — Decreased from $2,144,804 in Q3 2024, primarily due to lower license fees.
• Cash and Cash Equivalents: $2,039,853 — Increased significantly from $437,604 at Dec 31, 2024, largely due to financing activities.
• Proceeds from Warrant Exercise: $3,813,057 — Major contributor to increased cash, indicating reliance on equity financing.

Related Companies

BKII · BK

Frequently Asked Questions